dr holst glp 1 Exclusive interview: Jens Juul 📖 Opdagelsen af GLP-1 –

THIS YEAR, at the American College of Rheumatology (ACR) Convergence 2025, a dedicated session explored whether glucagon-like peptide-1...

In March, I fell prey to a scammy telehealth company

Build a winning GLP-1 pharma marketing strategy that balances demand, safety concerns, and differentiation in a competitive market.

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR 2025 Congress.“Our aim was to investigate whether GLP-1 receptor agonists could have a protective effect for the treatment of RA patients on JAK inhibitors to reduce cardiovascular

Chemist4U surveyed more than 3,500 UK adults to find out how they feel about weight loss, injections, and the arrival of these tablets.